Trump Administration Considers Shorter Brand Name Drug Protections

Trump Administration Considers Shorter Brand Name Drug Protections

The Trump administration is considering taking action to make some generic drugs available faster in the United States, potentially helping millions of people save money on their prescription costs.

This is one of many trade deals in the United States-Mexico-Canada Agreement (USMCA). It would allow intellectual property protection for medications made from organisms to be dropped from 10 years down to 5.

House Speaker Nancy Pelosi has been accused of slowing down USMCA negotiations. She defended herself at the recent UN climate conference, saying:

TEST

“We still have some issues that relate to enforcement because if you don’t have enforcement you just have a nice conversation and a list of nice things, but you do not have a fair deal for workers in any of the countries.”

The pharmaceutical industry, which doesn’t support changing the USMCA biologic patent rules, claims that the proposed changes would not affect the price of prescription drugs for the US.

Copyright 2019, UnitedVoice.com